Daiichi Sankyo Company, Limited (TYO:4568)
3,442.00
-101.00 (-2.85%)
Sep 22, 2025, 3:30 PM JST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 474.60B JPY in the quarter ending June 30, 2025, with 8.81% growth. This brings the company's revenue in the last twelve months to 1.92T, up 14.09% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
1,924.68B
Revenue Growth
+14.09%
P/S Ratio
3.31
Revenue / Employee
97.38M
Employees
19,765
Market Cap
6,370.94B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 1,886.26B | 284.57B | 17.77% |
Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Chugai Pharmaceutical | 1,196.21B |
HOYA Corporation | 876.09B |
Takeda Pharmaceutical Company | 4,480.25B |
Otsuka Holdings | 2,401.70B |
Terumo | 1,037.94B |
Astellas Pharma | 1,944.99B |
Shionogi & | 440.50B |
Olympus | 969.02B |
Daiichi Sankyo Company News
- 3 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses On WCLC 2025 Highlights (Transcript) - Seeking Alpha
- 3 days ago - Daiichi Sankyo Company, Limited (DSNKY) Discusses On WCLC 2025 Highlights (Transcript) - Seeking Alpha
- 3 days ago - Daiichi Sankyo Company, Limited (DSNKY) Special Call - Slideshow - Seeking Alpha
- 4 days ago - Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfaceomics - Business Wire
- 7 days ago - Daiichi Sankyo, Merck Say Raludotatug Deruxtecan Granted Breakthrough Therapy Designation - Nasdaq
- 13 days ago - 10 stocks to consider if you want alternatives to the expensive S&P 500 - Market Watch
- 15 days ago - Merck (MRK) and Daiichi Sankyo's Ifinatamab Deruxtecan Shows Promise in Lung Cancer Trial - GuruFocus
- 23 days ago - Daiichi Sankyo Announces the Development of a Fixed-Triple Combination Lipid-Lowering Tablet to Address Persistent Gaps in the Management of Elevated LDL-C - Business Wire